{"entity":{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","aka":["FLAMES"],"tldr":"A phase 3 trial testing IMP4927 in ovarian cancer, active and no longer recruiting.","summary":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer is a phase 3 interventional study registered as NCT04169997, led by Impact Therapeutics, and active but no longer recruiting on the registry. Official title: A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer. Planned enrolment is 404 participants (actual). The study started in 2019-12-24 and primary completion is expected in 2023-03-16. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT04169997","url":"https://clinicaltrials.gov/study/NCT04169997"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["imp4927"],"companies":["impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04169997","phase":"3","setting":"A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer","sponsor":"Impact Therapeutics","started":"2019-12-24","startedType":"actual","enrolled":404,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04169997/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/"}],"company":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}]}}